Ziltivekimab  (Synonyms: COR-001)

Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

2226654-05-1

Liquid

Colorless to light yellow

[Ziltivekimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Ziltivekimab on AHC2 biosensor, can bind IL-6 Protein, Human (N-His, HY-P7044B) with an affinity constant of 5.234E-10 M as determined in BLI assay.
• 
  Immobilized Human IL-6 Protein can bind Ziltivekimab. The EC₅₀ for this effect is 12.41 ng/mL.

• [1]. Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235.  [Content Brief]

  [2]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140.  [Content Brief]